NEW YORK (GenomeWeb) – Miragen Therapeutics this week announced that its research and development collaboration with France's Servier has been extended by two years to October 2016.
The companies first began working together in October 2011 under a three-year deal that gave Servier the rights to three of Miragen's preclinical microRNA inhibitor programs in cardiovascular disease in markets outside the US and Japan. These include ones focused on miR-208 for chronic heart failure, miR-15/195 for treating post-myocardial infarction remodeling, and a yet-to-be disclosed third program.
In exchange, Miragen received $45 million over the term of the arrangement, including upfront payments and milestones. Miragen also stands to receive royalties on product sales.
Financial terms of the extended partnership were not disclosed.